Shares of Doximity climbed after the San Francisco-based digital health platform raised its revenue outlook for fiscal 2027 and touted a strong safety showing for its artificial intelligence tool. The company now expects revenue of $671 million to $681 million for that year, up from its previous guidance, according to a Reuters report.
The upbeat forecast and AI announcement come as investors increasingly focus on how technology companies can turn AI hype into real, sustainable growth. For Doximity, the message is that its AI can fit into real clinical work without adding new risk.
What is Doximity Ask?
Doximity is best known for its professional network for doctors and other healthcare providers, which includes tools for messaging, telehealth, and medical news. The company has been pushing into AI with Doximity Ask, a model designed to answer clinical questions and assist physicians in their daily workflows.
CEO Jeff Tangney said Doximity Ask is reviewed by practicing clinicians who check answers for accuracy and supporting evidence. That human oversight is meant to address one of the biggest concerns about AI in medicine: the risk of generating incorrect or harmful advice.
The company said Doximity Ask ranked best among US-based models in the NOHARM benchmark, a test specifically designed to flag harmful medical responses. While the company did not disclose full details of the benchmark results, the claim is a notable endorsement for a tool that competes with larger tech players in the healthcare AI space.
Why the market reacted
Investors often reward companies that raise guidance, as it signals confidence in future growth. Doximity's upward revision suggests the company sees stronger demand for its platform and AI features than previously expected.
The move also comes at a time when healthcare technology stocks are under scrutiny. Many digital health companies have struggled to turn user growth into profits, and AI has become a key battleground for differentiation. Doximity's ability to point to a safety benchmark win could help it stand out.
That said, the fiscal 2027 forecast is still a couple of years out, and much can change between now and then. Investors will be watching whether the company can sustain its momentum in the nearer term.
What it means for investors
For everyday investors, the key takeaway is that Doximity is positioning itself as a leader in AI for healthcare, with a focus on safety and clinician oversight. The raised revenue forecast is a positive signal, but it's important to remember that guidance can be revised again, and AI benchmarks are just one measure of a company's long-term prospects.
Doximity's stock move also reflects a broader trend: companies that can credibly tie AI to revenue growth tend to be rewarded by the market. However, investors should be cautious about chasing single-day pops, especially when the news involves long-term forecasts.
As always, it's wise to consider how a stock fits into your overall portfolio and risk tolerance. The healthcare AI space is competitive, and Doximity will need to keep innovating to maintain its edge.
For more on how tech and healthcare stocks are moving, check out our coverage of tech outlooks ahead of the jobs report and how other companies are handling guidance changes.
